Global Gynecologic Cancer Market
Global Gynecologic Cancer Market

Gynecologic Cancer Comprehensive Study by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer, Cervical Cancer), Application (Hospital, Clinic, Other), Treatment (Chemotherapy, Radiation Therapy, Hormonal Therapy, Surgery, Immunotherapy, Targeted Therapy), Stages (Stage I Cancer, Stage II Cancer, Stage III Cancer, Stage IV Cancer) Players and Region - Global Market Outlook to 2025

Gynecologic Cancer Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 205 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Gynecologic Cancer Market Scope
Gynecologic cancer is any cancer that starts in a woman's reproductive organs. Five main types of cancer affect a woman's reproductive organs are cervical, ovarian, uterine, vaginal, and vulvar. As a group, they are referred to as gynecologic cancer. The sixth type of gynecologic cancer is a very rare fallopian tube cancer. Rapid innovations in devices and technological advancement have encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.

The Gynecologic Cancer market study is segmented by Type (Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer and Cervical Cancer), by Application (Hospital, Clinic and Other) and major geographies with country level break-up.

This is a consolidated market, there is a huge number of market players present in this market. There is a strong rivalry in this industry. The players highly focusing on business growth strategies such including new product launch, merger & acquisitions, Licensing partnerships, and others to become more competitive in the market. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Gynecologic Cancer market throughout the predicted period.

GlaxoSmithKline plc (United Kingdom), Becton, Dickinson and Company (United States), Eli Lilly and Company (United States), Bristol Myers Squibb Co. (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthcare GmbH (Germany), Quest Diagnostics Incorporated. (United States), Merck & Company, Inc. (United States), Novartis AG (Switzerland) and Pfizer, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Thermo Fisher Scientific (United States), Bio-Rad Technologies Inc. (United States) and Abbott (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Gynecologic Cancer market by Type, Application and Region.

On the basis of geography, the market of Gynecologic Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 25th February 2019, Roche has entered into an agreement to acquire Spark therapeutics. This acquisition will offer new opportunities of treatment of serious diseases.
In June 2020, Genelux Corporation, a privately-held, clinical-stage immuno-oncology company, announced that it has formed a Clinical Advisory Board (CAB) on gynecologic cancers that will guide the clinical development of its lead clinical-stage candidate, Olvi-Vec.
In Sept 2020, Cancer patient advocates and medical professionals in more than 20 countries are planning activities for World Gynecologic Oncology Day (World GO Day).

Market Trend
  • Advancements in Treatment of Gynecologic Cancer
  • Increasing Approval of New Drugs

Market Drivers
  • The Rising Occurrence of Various Types of Gynecologic Cancer Including Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer
  • Surging Investment on Research and Development in Gynecology

Opportunities
  • Enhancement in Healthcare Expenditure in Developed Regions
  • Huge Technological Advancements in Diagnostics Devices

Restraints
  • Patent Expiry of Various Major Drugs

Challenges
  • Lack of Proper Reimbursement Policies in the Developing Countries


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analyst and Strategic Business Planners, Gynecologic Cancer Diagnostics Devices and Drugs Manufacturers, Suppliers, and Distributors, Key Raw Material Manufacturers, Government Regulatory and Research Organizations and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Uterine Cancer
  • Ovarian Cancer
  • Vaginal Cancer
  • Vulvar Cancer
  • Cervical Cancer
By Application
  • Hospital
  • Clinic
  • Other
By Treatment
  • Chemotherapy
  • Radiation Therapy
  • Hormonal Therapy
  • Surgery
  • Immunotherapy
  • Targeted Therapy

By Stages
  • Stage I Cancer
  • Stage II Cancer
  • Stage III Cancer
  • Stage IV Cancer

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The Rising Occurrence of Various Types of Gynecologic Cancer Including Uterine Cancer, Ovarian Cancer, Vaginal Cancer, Vulvar Cancer
      • 3.2.2. Surging Investment on Research and Development in Gynecology
    • 3.3. Market Challenges
      • 3.3.1. Lack of Proper Reimbursement Policies in the Developing Countries
    • 3.4. Market Trends
      • 3.4.1. Advancements in Treatment of Gynecologic Cancer
      • 3.4.2. Increasing Approval of New Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gynecologic Cancer, by Type, Application, Treatment, Stages and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Gynecologic Cancer (Value)
      • 5.2.1. Global Gynecologic Cancer by: Type (Value)
        • 5.2.1.1. Uterine Cancer
        • 5.2.1.2. Ovarian Cancer
        • 5.2.1.3. Vaginal Cancer
        • 5.2.1.4. Vulvar Cancer
        • 5.2.1.5. Cervical Cancer
      • 5.2.2. Global Gynecologic Cancer by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
        • 5.2.2.3. Other
      • 5.2.3. Global Gynecologic Cancer by: Treatment (Value)
        • 5.2.3.1. Chemotherapy
        • 5.2.3.2. Radiation Therapy
        • 5.2.3.3. Hormonal Therapy
        • 5.2.3.4. Surgery
        • 5.2.3.5. Immunotherapy
        • 5.2.3.6. Targeted Therapy
      • 5.2.4. Global Gynecologic Cancer by: Stages (Value)
        • 5.2.4.1. Stage I Cancer
        • 5.2.4.2. Stage II Cancer
        • 5.2.4.3. Stage III Cancer
        • 5.2.4.4. Stage IV Cancer
      • 5.2.5. Global Gynecologic Cancer Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gynecologic Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Becton, Dickinson and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly and Company (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bristol Myers Squibb Co. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Siemens Healthcare GmbH (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quest Diagnostics Incorporated. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck & Company, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gynecologic Cancer Sale, by Type, Application, Treatment, Stages and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Gynecologic Cancer (Value)
      • 7.2.1. Global Gynecologic Cancer by: Type (Value)
        • 7.2.1.1. Uterine Cancer
        • 7.2.1.2. Ovarian Cancer
        • 7.2.1.3. Vaginal Cancer
        • 7.2.1.4. Vulvar Cancer
        • 7.2.1.5. Cervical Cancer
      • 7.2.2. Global Gynecologic Cancer by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
        • 7.2.2.3. Other
      • 7.2.3. Global Gynecologic Cancer by: Treatment (Value)
        • 7.2.3.1. Chemotherapy
        • 7.2.3.2. Radiation Therapy
        • 7.2.3.3. Hormonal Therapy
        • 7.2.3.4. Surgery
        • 7.2.3.5. Immunotherapy
        • 7.2.3.6. Targeted Therapy
      • 7.2.4. Global Gynecologic Cancer by: Stages (Value)
        • 7.2.4.1. Stage I Cancer
        • 7.2.4.2. Stage II Cancer
        • 7.2.4.3. Stage III Cancer
        • 7.2.4.4. Stage IV Cancer
      • 7.2.5. Global Gynecologic Cancer Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gynecologic Cancer: by Type(USD Million)
  • Table 2. Gynecologic Cancer Uterine Cancer , by Region USD Million (2014-2019)
  • Table 3. Gynecologic Cancer Ovarian Cancer , by Region USD Million (2014-2019)
  • Table 4. Gynecologic Cancer Vaginal Cancer , by Region USD Million (2014-2019)
  • Table 5. Gynecologic Cancer Vulvar Cancer , by Region USD Million (2014-2019)
  • Table 6. Gynecologic Cancer Cervical Cancer , by Region USD Million (2014-2019)
  • Table 7. Gynecologic Cancer: by Application(USD Million)
  • Table 8. Gynecologic Cancer Hospital , by Region USD Million (2014-2019)
  • Table 9. Gynecologic Cancer Clinic , by Region USD Million (2014-2019)
  • Table 10. Gynecologic Cancer Other , by Region USD Million (2014-2019)
  • Table 11. Gynecologic Cancer: by Treatment(USD Million)
  • Table 12. Gynecologic Cancer Chemotherapy , by Region USD Million (2014-2019)
  • Table 13. Gynecologic Cancer Radiation Therapy , by Region USD Million (2014-2019)
  • Table 14. Gynecologic Cancer Hormonal Therapy , by Region USD Million (2014-2019)
  • Table 15. Gynecologic Cancer Surgery , by Region USD Million (2014-2019)
  • Table 16. Gynecologic Cancer Immunotherapy , by Region USD Million (2014-2019)
  • Table 17. Gynecologic Cancer Targeted Therapy , by Region USD Million (2014-2019)
  • Table 18. Gynecologic Cancer: by Stages(USD Million)
  • Table 19. Gynecologic Cancer Stage I Cancer , by Region USD Million (2014-2019)
  • Table 20. Gynecologic Cancer Stage II Cancer , by Region USD Million (2014-2019)
  • Table 21. Gynecologic Cancer Stage III Cancer , by Region USD Million (2014-2019)
  • Table 22. Gynecologic Cancer Stage IV Cancer , by Region USD Million (2014-2019)
  • Table 23. South America Gynecologic Cancer, by Country USD Million (2014-2019)
  • Table 24. South America Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 25. South America Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 26. South America Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 27. South America Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 28. Brazil Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 29. Brazil Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 30. Brazil Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 31. Brazil Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 32. Argentina Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 33. Argentina Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 34. Argentina Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 35. Argentina Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 36. Rest of South America Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 37. Rest of South America Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 38. Rest of South America Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 39. Rest of South America Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 40. Asia Pacific Gynecologic Cancer, by Country USD Million (2014-2019)
  • Table 41. Asia Pacific Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 42. Asia Pacific Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 43. Asia Pacific Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 44. Asia Pacific Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 45. China Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 46. China Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 47. China Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 48. China Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 49. Japan Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 50. Japan Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 51. Japan Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 52. Japan Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 53. India Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 54. India Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 55. India Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 56. India Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 57. South Korea Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 58. South Korea Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 59. South Korea Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 60. South Korea Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 61. Taiwan Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 62. Taiwan Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 63. Taiwan Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 64. Taiwan Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 65. Australia Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 66. Australia Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 67. Australia Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 68. Australia Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 71. Rest of Asia-Pacific Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 72. Rest of Asia-Pacific Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 73. Europe Gynecologic Cancer, by Country USD Million (2014-2019)
  • Table 74. Europe Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 75. Europe Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 76. Europe Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 77. Europe Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 78. Germany Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 79. Germany Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 80. Germany Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 81. Germany Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 82. France Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 83. France Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 84. France Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 85. France Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 86. Italy Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 87. Italy Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 88. Italy Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 89. Italy Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 90. United Kingdom Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 91. United Kingdom Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 92. United Kingdom Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 93. United Kingdom Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 94. Netherlands Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 95. Netherlands Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 96. Netherlands Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 97. Netherlands Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 98. Rest of Europe Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 99. Rest of Europe Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 100. Rest of Europe Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 101. Rest of Europe Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 102. MEA Gynecologic Cancer, by Country USD Million (2014-2019)
  • Table 103. MEA Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 104. MEA Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 105. MEA Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 106. MEA Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 107. Middle East Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 108. Middle East Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 109. Middle East Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 110. Middle East Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 111. Africa Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 112. Africa Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 113. Africa Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 114. Africa Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 115. North America Gynecologic Cancer, by Country USD Million (2014-2019)
  • Table 116. North America Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 117. North America Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 118. North America Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 119. North America Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 120. United States Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 121. United States Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 122. United States Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 123. United States Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 124. Canada Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 125. Canada Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 126. Canada Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 127. Canada Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 128. Mexico Gynecologic Cancer, by Type USD Million (2014-2019)
  • Table 129. Mexico Gynecologic Cancer, by Application USD Million (2014-2019)
  • Table 130. Mexico Gynecologic Cancer, by Treatment USD Million (2014-2019)
  • Table 131. Mexico Gynecologic Cancer, by Stages USD Million (2014-2019)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Gynecologic Cancer: by Type(USD Million)
  • Table 143. Gynecologic Cancer Uterine Cancer , by Region USD Million (2020-2025)
  • Table 144. Gynecologic Cancer Ovarian Cancer , by Region USD Million (2020-2025)
  • Table 145. Gynecologic Cancer Vaginal Cancer , by Region USD Million (2020-2025)
  • Table 146. Gynecologic Cancer Vulvar Cancer , by Region USD Million (2020-2025)
  • Table 147. Gynecologic Cancer Cervical Cancer , by Region USD Million (2020-2025)
  • Table 148. Gynecologic Cancer: by Application(USD Million)
  • Table 149. Gynecologic Cancer Hospital , by Region USD Million (2020-2025)
  • Table 150. Gynecologic Cancer Clinic , by Region USD Million (2020-2025)
  • Table 151. Gynecologic Cancer Other , by Region USD Million (2020-2025)
  • Table 152. Gynecologic Cancer: by Treatment(USD Million)
  • Table 153. Gynecologic Cancer Chemotherapy , by Region USD Million (2020-2025)
  • Table 154. Gynecologic Cancer Radiation Therapy , by Region USD Million (2020-2025)
  • Table 155. Gynecologic Cancer Hormonal Therapy , by Region USD Million (2020-2025)
  • Table 156. Gynecologic Cancer Surgery , by Region USD Million (2020-2025)
  • Table 157. Gynecologic Cancer Immunotherapy , by Region USD Million (2020-2025)
  • Table 158. Gynecologic Cancer Targeted Therapy , by Region USD Million (2020-2025)
  • Table 159. Gynecologic Cancer: by Stages(USD Million)
  • Table 160. Gynecologic Cancer Stage I Cancer , by Region USD Million (2020-2025)
  • Table 161. Gynecologic Cancer Stage II Cancer , by Region USD Million (2020-2025)
  • Table 162. Gynecologic Cancer Stage III Cancer , by Region USD Million (2020-2025)
  • Table 163. Gynecologic Cancer Stage IV Cancer , by Region USD Million (2020-2025)
  • Table 164. South America Gynecologic Cancer, by Country USD Million (2020-2025)
  • Table 165. South America Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 166. South America Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 167. South America Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 168. South America Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 169. Brazil Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 170. Brazil Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 171. Brazil Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 172. Brazil Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 173. Argentina Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 174. Argentina Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 175. Argentina Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 176. Argentina Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 177. Rest of South America Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 178. Rest of South America Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 179. Rest of South America Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 180. Rest of South America Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 181. Asia Pacific Gynecologic Cancer, by Country USD Million (2020-2025)
  • Table 182. Asia Pacific Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 183. Asia Pacific Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 184. Asia Pacific Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 185. Asia Pacific Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 186. China Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 187. China Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 188. China Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 189. China Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 190. Japan Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 191. Japan Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 192. Japan Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 193. Japan Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 194. India Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 195. India Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 196. India Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 197. India Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 198. South Korea Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 199. South Korea Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 200. South Korea Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 201. South Korea Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 202. Taiwan Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 203. Taiwan Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 204. Taiwan Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 205. Taiwan Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 206. Australia Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 207. Australia Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 208. Australia Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 209. Australia Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 210. Rest of Asia-Pacific Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 211. Rest of Asia-Pacific Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 212. Rest of Asia-Pacific Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 213. Rest of Asia-Pacific Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 214. Europe Gynecologic Cancer, by Country USD Million (2020-2025)
  • Table 215. Europe Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 216. Europe Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 217. Europe Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 218. Europe Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 219. Germany Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 220. Germany Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 221. Germany Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 222. Germany Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 223. France Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 224. France Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 225. France Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 226. France Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 227. Italy Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 228. Italy Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 229. Italy Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 230. Italy Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 231. United Kingdom Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 232. United Kingdom Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 233. United Kingdom Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 234. United Kingdom Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 235. Netherlands Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 236. Netherlands Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 237. Netherlands Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 238. Netherlands Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 239. Rest of Europe Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 240. Rest of Europe Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 241. Rest of Europe Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 242. Rest of Europe Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 243. MEA Gynecologic Cancer, by Country USD Million (2020-2025)
  • Table 244. MEA Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 245. MEA Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 246. MEA Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 247. MEA Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 248. Middle East Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 249. Middle East Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 250. Middle East Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 251. Middle East Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 252. Africa Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 253. Africa Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 254. Africa Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 255. Africa Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 256. North America Gynecologic Cancer, by Country USD Million (2020-2025)
  • Table 257. North America Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 258. North America Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 259. North America Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 260. North America Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 261. United States Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 262. United States Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 263. United States Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 264. United States Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 265. Canada Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 266. Canada Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 267. Canada Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 268. Canada Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 269. Mexico Gynecologic Cancer, by Type USD Million (2020-2025)
  • Table 270. Mexico Gynecologic Cancer, by Application USD Million (2020-2025)
  • Table 271. Mexico Gynecologic Cancer, by Treatment USD Million (2020-2025)
  • Table 272. Mexico Gynecologic Cancer, by Stages USD Million (2020-2025)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gynecologic Cancer: by Type USD Million (2014-2019)
  • Figure 5. Global Gynecologic Cancer: by Application USD Million (2014-2019)
  • Figure 6. Global Gynecologic Cancer: by Treatment USD Million (2014-2019)
  • Figure 7. Global Gynecologic Cancer: by Stages USD Million (2014-2019)
  • Figure 8. South America Gynecologic Cancer Share (%), by Country
  • Figure 9. Asia Pacific Gynecologic Cancer Share (%), by Country
  • Figure 10. Europe Gynecologic Cancer Share (%), by Country
  • Figure 11. MEA Gynecologic Cancer Share (%), by Country
  • Figure 12. North America Gynecologic Cancer Share (%), by Country
  • Figure 13. Global Gynecologic Cancer share by Players 2019 (%)
  • Figure 14. Global Gynecologic Cancer share by Players (Top 3) 2019(%)
  • Figure 15. Global Gynecologic Cancer share by Players (Top 5) 2019(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2019
  • Figure 19. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 20. Becton, Dickinson and Company (United States) Revenue: by Geography 2019
  • Figure 21. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 23. Bristol Myers Squibb Co. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol Myers Squibb Co. (United States) Revenue: by Geography 2019
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 27. Siemens Healthcare GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Siemens Healthcare GmbH (Germany) Revenue: by Geography 2019
  • Figure 29. Quest Diagnostics Incorporated. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Quest Diagnostics Incorporated. (United States) Revenue: by Geography 2019
  • Figure 31. Merck & Company, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Merck & Company, Inc. (United States) Revenue: by Geography 2019
  • Figure 33. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Novartis AG (Switzerland) Revenue: by Geography 2019
  • Figure 35. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer, Inc. (United States) Revenue: by Geography 2019
  • Figure 37. Global Gynecologic Cancer: by Type USD Million (2020-2025)
  • Figure 38. Global Gynecologic Cancer: by Application USD Million (2020-2025)
  • Figure 39. Global Gynecologic Cancer: by Treatment USD Million (2020-2025)
  • Figure 40. Global Gynecologic Cancer: by Stages USD Million (2020-2025)
  • Figure 41. South America Gynecologic Cancer Share (%), by Country
  • Figure 42. Asia Pacific Gynecologic Cancer Share (%), by Country
  • Figure 43. Europe Gynecologic Cancer Share (%), by Country
  • Figure 44. MEA Gynecologic Cancer Share (%), by Country
  • Figure 45. North America Gynecologic Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • GlaxoSmithKline plc (United Kingdom)
  • Becton, Dickinson and Company (United States)
  • Eli Lilly and Company (United States)
  • Bristol Myers Squibb Co. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Siemens Healthcare GmbH (Germany)
  • Quest Diagnostics Incorporated. (United States)
  • Merck & Company, Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
Additional players considered in the study are as follows:
Thermo Fisher Scientific (United States) , Bio-Rad Technologies Inc. (United States) , Abbott (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation